参考文献/References:
[1] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories,1990—2019:a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet,2020,396(10258):1204-1222.
[2] 国家卫生计生委合理用药专家委员会,中国药师协会. 冠心病合理用药指南(第2版)[J].中国医学前沿杂志（电子版）,2018,10(6):1-130.
[3] Waterbury TM,Tarantini G,Vogel B,et al. Non-atherosclerotic causes of acute coronary syndromes[J]. Nat Rev Cardiol,2020,17(4):229-241.
[4] Hedin U,Matic LP. Recent advances in therapeutic targeting of inflammation in atherosclerosis[J]. J Vasc Surg,2019,69(3):944-951.
[5] Silvestre-Roig C,Braster Q,Ortega-Gomez A,et al. Neutrophils as regulators of cardiovascular inflammation[J]. Nat Rev Cardiol,2020,17(6):327-340.
[6] Mantovani A,Dinarello CA,Molgora M,et al. Interleukin-1 and related cytokines in the regulation of inflammation and immunity[J]. Immunity,2019,50(4):778-795.
[7] Migliorini P,Italiani P,Pratesi F,et al. The IL-1 family cytokines and receptors in autoimmune diseases[J]. Autoimmun Rev,2020,19(9):102617.
[8] Cavalli G,Colafrancesco S,Emmi G,et al. Interleukin 1α:a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases[J]. Autoimmun Rev,2021,20(3):102763.
[9] Suzuki K,Murtuza B,Smolenski RT,et al. Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis[J]. Circulation,2001,104(12 suppl 1):I308-I313.
[10] Furuichi K,Wada T,Iwata Y,et al. Interleukin-1-dependent sequential chemokine expression and inflammatory cell infiltration in ischemia-reperfusion injury[J]. Crit Care Med,2006,34 (9):2447-2455.
[11] Pinteaux E,Rothwell NJ,Boutin H. Neuroprotective actions of endogenous interleukin-1 receptor antagonist(IL-1ra) are mediated by glia[J]. Glia,2006,53(5):551-556.
[12] Bujak M,Dobaczewski M,Chatila K,et al. Interleukin-1 receptor typeⅠsignaling critically regulates infarct healing and cardiac remodeling[J]. Am J Pathol,2008,173(1):57-67.
[13] Mauro AG,Mezzaroma E,Torrado J,et al. Reduction of myocardial ischemia-reperfusion injury by inhibiting interleukin-1 alpha[J]. J Cardiovasc Pharmacol,2017,69(3):156-160.
[14] The Interleukin 1 Genetics Consortium. Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist:a Mendelian randomisation analysis[J]. Lancet Diabetes Endocrinol,2015,3(4):243-253.
[15] Abbate A,van Tassell BW,Biondi-Zoccai G,et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study][J]. Am J Cardiol,2013,111(10):1394-1400.
[16] Abbate A,Kontos MC,Grizzard JD,et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction(Virginia Commonwealth University Anakinra Remodeling Trial[VCU-ART] Pilot study)[J]. Am J Cardiol,2010,105(10):1371-1377.e1.
[17] Morton AC,Rothman AMK,Greenwood JP,et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes:the MRC-ILA Heart Study[J]. Eur Heart J,2015,36(6):377-384.
[18] Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity[J]. Immunol Rev,2018,281(1):8-27.
[19] Kim B,Lee Y,Kim E,et al. The interleukin-1α precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines[J]. Front Immunol,2013,4:391.
[20] Libby P. Interleukin-1 beta as a target for atherosclerosis therapy:biological basis of CANTOS and beyond[J]. J Am Coll Cardiol,2017,70(18):2278-2289.
[21] Tong Y,Wang Z,Cai L,et al. NLRP3 inflammasome and its central role in the cardiovascular diseases[J]. Oxid Med Cell Longev,2020,2020:4293206.
[22] Shikama Y,Aki N,Hata A,et al. Palmitate-stimulated monocytes induce adhesion molecule expression in endothelial cells via IL-1 signaling pathway[J]. J Cell Physiol,2015,230(3):732-742.
[23] Ridker PM,Everett BM,Thuren T,et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Eng J Med,2017,377(12):1119-1131.
[24] Ridker PM,MacFadyen JG,Thuren T,et al. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab:further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis[J]. Eur Heart J,2020,41(23):2153-2163.
[25] Novick D,Kim S,Kaplanski G,et al. Interleukin-18,more than a Th1 cytokine[J]. Semin Immunol,2013,25(6):439-448.
[26] Kaptoge S,Seshasai SR,Gao P,et al. Inflammatory cytokines and risk of coronary heart disease:new prospective study and updated meta-analysis[J]. Eur Heart J,2014,35(9):578-589.
[27] ?kerblom A,James SK,Lakic TG,et al. Interleukin-18 in patients with acute coronary syndromes[J]. Clin Cardiol,2019,42(12):1202-1209.
[28] Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases[J]. Nat Rev Rheumatol,2019,15(10):612-632.
[29] Cayrol C,Girard JP. Interleukin-33(IL-33):a nuclear cytokine from the IL-1 family[J] . Immunol Rev,2018,281(1):154-168.
[30] Bertheloot D,Latz E. HMGB1,IL-1α,IL-33 and S100 proteins:dual-function alarmins[J]. Cell Mol Immunol,2017,14(1):43-64.
[31] Gurgone D,McShane L,McSharry C,et al. Cytokines at the interplay between asthma and atherosclerosis?[J]. Front Pharmacol,2020,11:166.
[32] Miller AM,Xu D,Asquith DL,et al. IL-33 reduces the development of atherosclerosis[J]. J Exp Med,2008,205(2):339-346.
[33] Martin P,Palmer G,Rodriguez E,et al. Atherosclerosis severity is not affected by a deficiency in IL-33/ST2 signaling[J]. Immun Inflamm Dis,2015,3(3):239-246.
[34] Liu CL,Shen DL,Zhu K,et al. Characterization of interleukin-33 and matrix metalloproteinase-28 in serum and their association with disease severity in patients with coronary heart disease[J]. Coron Artery Dis,2014,25(6):498-504.
[35] Al Shahi H,Shimada K,Miyauchi K,et al. Elevated circulating levels of inflammatory markers in patients with acute coronary syndrome[J]. Int J Vasc Med,2015,2015:805375.
[36] Demyanets S,Speidl WS,Tentzeris I,et al. Soluble ST2 and interleukin-33 levels in coronary artery disease:relation to disease activity and adverse outcome[J]. PLoS One,2014,9(4):e95055.
[37] Han Y,Huard A,Mora J,et al. IL-36 family cytokines in protective versus destructive inflammation[J]. Cell Signal,2020,75:109773.
[38] Tian Y,Ling XY,Chen DL,et al. Interleukin-36 receptor antagonist attenuates atherosclerosis development by inhibiting NLRP3 inflammasome[J]. J Cell Physiol,2020,235(12):9992-9996.
[39] Jia H,Liu J,Han B. Reviews of interleukin-37:functions,receptors,and roles in diseases[J]. Biomed Res Int,2018,2018:3058640.
[40] Li H,Shen C,Chen B,et al. Interleukin-37 is increased in peripheral blood mononuclear cells of coronary heart disease patients and inhibits the inflammatory reaction[J]. Mol Med Rep,2020,21(1):151-160.
[41] Lotfy H,Moaaz M,Moaaz M. The novel role of IL-37 to enhance the anti-inflammatory response of regulatory T cells in patients with peripheral atherosclerosis[J]. Vascular,2020,28(5):629-642.
[42] Zhong Y,Yu K,Wang X,et al. Elevated plasma IL-38 concentrations in patients with acute ST-segment elevation myocardial infarction and their dynamics after reperfusion treatment[J]. Mediators Inflamm,2015,2015:490120.
[43] Wei Y,Lan Y,Zhong Y,et al. Interleukin-38 alleviates cardiac remodelling after myocardial infarction[J]. J Cell Mol Med,2020,24(1):371-384.
相似文献/References:
[1]韩雅君,朱慧,王丽媛,等.虚拟组织学对急性冠状动脉综合征患者斑块评价研究进展[J].心血管病学进展,2015,(5):641.[doi:10.3969/j.issn.1004-3934.2015.05.031]
HAN Yajun,ZHU Hui,WANG Liyuan,et al.Evaluating Plaque in Patients with Acute Coronary Syndrome by Intravascular
Ultrasound with Virtual Histology[J].Advances in Cardiovascular Diseases,2015,(1):641.[doi:10.3969/j.issn.1004-3934.2015.05.031]
[2]郭远林.急性冠状动脉综合征风险评估方法学进展[J].心血管病学进展,2015,(6):681.[doi:10.3969/j.issn.1004-3934.2015.06.007]
GUO Yuanlin,YAN Hongbin.Progress in Tools for Risk Assessment of Acute Coronary Syndromes[J].Advances in Cardiovascular Diseases,2015,(1):681.[doi:10.3969/j.issn.1004-3934.2015.06.007]
[3]魏恒争,木胡牙提.比伐卢定在急性冠状动脉综合征患者PCI中的应用进展[J].心血管病学进展,2015,(6):725.[doi:10.3969/j.issn.1004-3934.2015.06.017]
WEI Hengzheng,MUHU Yati.Advance in Research of Bivalirudin During Percutaneous Coronary Intervention
in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2015,(1):725.[doi:10.3969/j.issn.1004-3934.2015.06.017]
[4]丁晓彤 张欣 左海奇 孙雨萌 贾赫 刘宏伟 孙鑫 孙延明 王岚峰 王姝.应激性心肌病诊治进展[J].心血管病学进展,2019,(5):778.[doi:10.16806/j.cnki.issn.1004-3934. 2019.05.028]
DING Xiaotong,ZHANG Xin,ZUO Haiqi,et al.Diagnosis and Treatment of Takotsubo Sydrome[J].Advances in Cardiovascular Diseases,2019,(1):778.[doi:10.16806/j.cnki.issn.1004-3934. 2019.05.028]
[5]陈纪元 陆泓雨 贺子熠 韩江莉.冠心病合并慢性肾脏病患者P2Y12受体拮抗剂治疗进展[J].心血管病学进展,2022,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
CHEN Jiyuan,LU Hongyu,HE Ziyi,et al.P2Y12 Antagonists for Patients with Chronic Kidney Diseases and Coronary Heart Diseases[J].Advances in Cardiovascular Diseases,2022,(1):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]